Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

Sponsor
University Hospital, Bonn
Study ID
NCT01914159
Phase
PHASE2
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.

Key Dates

First listed
Aug 1, 2013
Start date
Feb 28, 2013
Status verified
Jul 2019
Primary completion
Mar 31, 2016
Completion
Mar 31, 2016

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab

Primary Outcome Measure

Best-corrected Visual Acuity [ Time Frame: 12 months ]

Related Studies